Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

261
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
261
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

141
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
141
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

309
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
309
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

169
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
169
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

449
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
449
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

272
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
272

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Photodynamic therapy for primary tracheobronchial malignancy in Northwestern China.

Photodiagnosis and photodynamic therapy·2021
Same author

Influence of pore water phase change on service performance for permeable pavement in Sponge City.

Water science and technology : a journal of the International Association on Water Pollution Research·2021
Same author

The Effect of Social Media Use on Depressive Symptoms in Older Adults with Self-Reported Hearing Impairment: An Empirical Study.

Healthcare (Basel, Switzerland)·2021
Same author

Investigation on Dynamic Characteristics of AlGaN/GaN Lateral Schottky Barrier Diode.

Micromachines·2021
Same author

Impact of intraoperative medial collateral ligament injury on outcomes after total knee arthroplasty: a meta-analysis and systematic review.

Journal of orthopaedic surgery and research·2021
Same author

Strong and weak cross-inheritance of substance use disorders in a nationally representative sample.

Molecular psychiatry·2021

Related Experiment Video

Updated: Jan 4, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.4K

Individualizing Therapy in Lupus Nephritis.

Yu An1, Haitao Zhang1, Zhihong Liu1

  • 1National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.

Kidney International Reports
|November 9, 2019
PubMed
Summary

Combination therapy for lupus nephritis (LN) offers improved efficacy and reduced toxicity. This approach, combining corticosteroids, mycophenolate mofetil, and calcineurin inhibitors, aims for long-term remission in LN patients.

Keywords:
combination therapyefficacylupus nephritismolecular basis

More Related Videos

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.5K
Murine Bilateral Renal Lymphadenectomy
06:20

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

6

Related Experiment Videos

Last Updated: Jan 4, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

3.4K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

18.5K
Murine Bilateral Renal Lymphadenectomy
06:20

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

6

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Lupus nephritis (LN) requires rapid remission and sustained response with minimal toxicity.
  • Current treatments aim for synergistic effects using multiple drugs at lower doses.
  • Combination therapy is explored to enhance therapeutic outcomes in LN.

Purpose of the Study:

  • To review evidence on combination therapies for lupus nephritis.
  • To focus on triple therapy: high-dose corticosteroids, mycophenolate mofetil (MMF), and low-dose calcineurin inhibitors (CNI).
  • To discuss the rationale, efficacy, safety, and molecular mechanisms of this combination therapy.

Main Methods:

  • Review of available clinical evidence on combination therapies for LN.
  • Focus on studies combining high-dose corticosteroids with MMF and low-dose CNI.
  • Analysis of therapeutic efficacy, safety profiles, and molecular underpinnings.

Main Results:

  • Combination therapy, particularly triple therapy (corticosteroids, MMF, CNI), shows promise for improved therapeutic efficacy in LN.
  • This strategy aims to achieve additive or synergistic effects while minimizing drug toxicity.
  • Evidence supports the potential for enhanced remission rates and long-term disease control.

Conclusions:

  • Combination therapy, especially triple therapy, represents a significant advancement in lupus nephritis treatment.
  • Emerging approaches build upon combination strategies, moving towards personalized medicine in LN.
  • Further research and clinical trials are crucial to optimize these treatments and improve patient outcomes.